Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | BRS3 | P32247 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30880292 | 1.00 | CNR2 (0.47) | CNR2CNR1BRS3SLC6A3ALDH1A1 | |
| SCHEMBL30880291 | 1.00 | CNR2 (0.47) | CNR2CNR1BRS3SLC6A3ALDH1A1 | |
| SCHEMBL17448496 | 0.86 | CNR2 (0.34) | CNR2CNR1SLC6A3ESR1ESR2 | |
| SCHEMBL28354748 | 0.84 | SLC6A3 (0.35) | CNR2CNR1SLC6A3ALDH1A1ESR1 | |
| SCHEMBL897783 | 0.82 | APP (0.41) | ALDH1A1ESR1ESR2 | |
| SCHEMBL29660078 | 0.82 | APP (0.41) | ALDH1A1ESR1ESR2 | |
| SCHEMBL19296748 | 0.80 | ESR1 (0.33) | SLC6A3ESR1ESR2MTNR1AMTNR1B | |
| SCHEMBL29962699 | 0.80 | ESR1 (0.34) | SLC6A3ALDH1A1ESR1ESR2NR1H4 | |
| SCHEMBL17434660 | 0.80 | ESR1 (0.34) | SLC6A3ALDH1A1ESR1ESR2NR1H4 | |
| SCHEMBL13264181 | 0.80 | CNR1 (0.46) | CNR2CNR1BRS3ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3848361-B1 | METHOD OF PRODUCING TETRACYCLIC COMPOUND | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2025-01-22 | — | — | EP | disclosed |
| CN-112585126-B | Process for preparing tetracyclic compounds | 中外制药株式会社 | 2024-05-07 | — | — | CN | disclosed |
| US-11939322-B2 | Method for producing tetracyclic compound | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-03-26 | — | — | US | disclosed |
| US-20220372025-A1 | METHOD FOR PRODUCING TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2022-11-24 | — | — | US | disclosed |
| EP-3848361-A1 | METHOD OF PRODUCING TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2021-07-14 | — | — | EP | disclosed |
| CN-112585126-A | Tetracyclic compounds | 中外制药株式会社 | 2021-03-30 | — | — | CN | disclosed |
| CN-108178743-A | A kind of Ai Le replaces the preparation method of Buddhist nun's key intermediate | 安庆奇创药业有限公司 | 2018-06-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220372025-A1 | METHOD FOR PRODUCING TETRACYCLIC COMPOUND | CYP1B1, CYP4B1, PAICS | CNR2 694/4885CNR1 994/4885BRS3 3557/4885 |
| US-11939322-B2 | Method for producing tetracyclic compound | CYP1B1, CYP4B1, PAICS | CNR2 694/4885CNR1 994/4885BRS3 3557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.